The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans… The post RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next? appeared on BitcoinEthereumNews.com. Secretary of Health and Human Services Robert F. Kennedy Jr. The Associated Press Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there. Tylenol may be only the beginning. For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us. On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access. Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.) One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues. Another frequent target of Kennedy’s are statins, which more than 92 million Americans…

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

2025/09/26 19:16

Secretary of Health and Human Services Robert F. Kennedy Jr.

The Associated Press

Tylenol maker Kenvue is reeling after unsupported claims that its popular drug causes autism. Kennedy is unlikely to stop there.

Tylenol may be only the beginning.

For years, Robert F. Kennedy Jr. has railed against a number of medications and therapeutics claiming without scientific consensus or evidence that they cause some kind of harm — autism (Tylenol), suicidal thoughts (Ozempic). Now, as President Trump’s head of Health and Human Services, he’s begun turning his opinions into public policy. His Make American Healthy Again initiative has already made it harder for people to get vaccinated against COVID-19 and pushed unverified claims about Tylenol, and he’s just getting started. So what might be next? Kennedy’s already told us.

On Monday, Kennedy and FDA Commissioner Marty Makary wrote in a letter to 22 Republican attorneys general that the FDA was reviewing evidence about the safety of abortion drug, mifepristone, which is used in nearly two-thirds of medical abortions. If access to the pill were restricted, it would significantly cut back on abortion access.

Another big target: antidepressants. During Kennedy’s confirmation hearings, he falsely claimed that people have a harder time stopping the use of serotonin-based antidepressants “than people have getting off of heroin.” He’s also made the unfounded claim that teenagers who use them are more likely to commit school shootings (they aren’t.)

One of the goals of Kennedy’s “Make America Healthy Again” movement is to “assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors.” Any restrictions on them would be a grave concern to the approximately 11% of the population that uses them to treat depression, anxiety and other issues.

Another frequent target of Kennedy’s are statins, which more than 92 million Americans take to prevent heart disease and lower cholesterol. Most studies find that statins are both safe and help to prevent serious heart disease, which is the number one killer of Americans.

Yet Children’s Health Defense, the organization Kennedy founded, has published articles questioning the relationship of cholesterol to heart disease, with one calling them “overprescribed and unnecessary.” And earlier this year, as HHS Secretary, Kennedy claimed on a podcast that pharmaceutical companies manipulated studies to show they work.

One of the rationales for the agency’s recent crackdown on pharmaceutical ads is increased uptake of the drugs. Statins were the drugs of an older generation. Also in the crosshairs are newer innovations, like the increasingly popular GLP-1s used to treat diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). These drugs have recently been approved for additional health problems, such as sleep apnea, and are even being investigated for drug addiction.

That remarkable success hasn’t stopped Kennedy from criticizing their cost (they are expensive) and making false claims about them. For example, he falsely said that Novo Nordisk, which makes Ozempic, doesn’t market it in Europe. (It does.) He’s also said that ensuring Americans eat a good diet would solve the obesity problem–but multiple clinical studies have shown that GLP-1s are vastly superior to diet alone to helping people not only lose weight but keep it off.

In a first jab at their use, Kennedy rejected a plan to have Medicare cover the cost of GLP-1 drugs for obesity, which would have given 7 million Americans access to them, in April. (Medicare already covers these treatments for diabetes.) Could more restrictions on their use be seen down the road?

“They’re counting on selling it to Americans because we’re so stupid and so addicted to drugs,” Kennedy told viewers of Fox News about Ozempic and its manufacturer Novo Nordisk.

It’s not clear what, if anything, would change his mind.

MORE FROM FORBES

ForbesTrump’s Unproven Claims About Tylenol And Autism Are Reaching Millions On TikTokForbesRFK Jr.’s CDC Is Poised To Restrict Vaccines Even FurtherForbesThis Startup Hit A $3.25 Billion Valuation Building Software To Fix Drug Pricing

Source: https://www.forbes.com/sites/alexknapp/2025/09/26/rfk-jr-is-targeting-vaccines-and-tylenol-are-prozac-and-ozempic-next/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

CEO Sandeep Nailwal Shared Highlights About RWA on Polygon

CEO Sandeep Nailwal Shared Highlights About RWA on Polygon

The post CEO Sandeep Nailwal Shared Highlights About RWA on Polygon appeared on BitcoinEthereumNews.com. Polygon CEO Sandeep Nailwal highlighted Polygon’s lead in global bonds, Spiko US T-Bill, and Spiko Euro T-Bill. Polygon published an X post to share that its roadmap to GigaGas was still scaling. Sentiments around POL price were last seen to be bearish. Polygon CEO Sandeep Nailwal shared key pointers from the Dune and RWA.xyz report. These pertain to highlights about RWA on Polygon. Simultaneously, Polygon underlined its roadmap towards GigaGas. Sentiments around POL price were last seen fumbling under bearish emotions. Polygon CEO Sandeep Nailwal on Polygon RWA CEO Sandeep Nailwal highlighted three key points from the Dune and RWA.xyz report. The Chief Executive of Polygon maintained that Polygon PoS was hosting RWA TVL worth $1.13 billion across 269 assets plus 2,900 holders. Nailwal confirmed from the report that RWA was happening on Polygon. The Dune and https://t.co/W6WSFlHoQF report on RWA is out and it shows that RWA is happening on Polygon. Here are a few highlights: – Leading in Global Bonds: Polygon holds 62% share of tokenized global bonds (driven by Spiko’s euro MMF and Cashlink euro issues) – Spiko U.S.… — Sandeep | CEO, Polygon Foundation (※,※) (@sandeepnailwal) September 17, 2025 The X post published by Polygon CEO Sandeep Nailwal underlined that the ecosystem was leading in global bonds by holding a 62% share of tokenized global bonds. He further highlighted that Polygon was leading with Spiko US T-Bill at approximately 29% share of TVL along with Ethereum, adding that the ecosystem had more than 50% share in the number of holders. Finally, Sandeep highlighted from the report that there was a strong adoption for Spiko Euro T-Bill with 38% share of TVL. He added that 68% of returns were on Polygon across all the chains. Polygon Roadmap to GigaGas In a different update from Polygon, the community…
Share
BitcoinEthereumNews2025/09/18 01:10
Share
Ethereum applications at the On-chain Summit

Ethereum applications at the On-chain Summit

The post Ethereum applications at the On-chain Summit appeared on BitcoinEthereumNews.com. Ethereum applications dominated discussion today at the Global On-chain Asset Summit in Singapore, hosted by HashKey Group, where Vitalik Buterin and Dr. Xiao Feng outlined practical paths for scaling, identity and risk control on-chain. What was the main message from the summit about l1 l2 application differences? Speakers drew a clear line between Layer 1 and Layer 2 use cases. L1 remains the canonical base for settlement and shared security. L2s are framed as the layer for high throughput and lower fees. In this context, developers should design with cross-layer interoperability in mind. Applications that need finality and censorship resistance will favor L1. By contrast, high-frequency use cases — such as prediction markets and micropayments — gain from L2 throughput and reduced costs. How does this affect developers choosing where to deploy? Teams must weigh latency, fees and trust assumptions. Many prototype on L2, then shift critical settlement logic to L1 when guarantees matter. Tooling for bridging and observability is improving, which reduces migration friction. How did the speakers address ethereum prediction markets and their scaling? Panelists discussed the promise of ethereum prediction markets for price discovery and hedging. They underlined that such markets need fast finality and low fees to operate efficiently. As a result, builders plan to run market engines on L2 or rollups while anchoring outcomes on L1. This hybrid model preserves security and delivers the speed traders require. However, throughput targets and oracle designs remain under debate. Are there regulatory or market risks traders should watch? Yes. Speakers flagged regulatory scrutiny and liquidity fragmentation as material risks. Choosing venues with transparent on-chain settlement and reputable layers reduces counterparty exposure. What role will zk identity proofs play in on-chain user models? Experts positioned zk identity proofs as a core tool for privacy-preserving KYC, Sybil resistance and reputation…
Share
BitcoinEthereumNews2025/10/07 01:23
Share